Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Summary

V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Percutaneous Coronary Intervention
• Peripheral Endovascular Intervention

Eligibility basics and study details

Study type

Interventional

Phase

Phase 4

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Duke University

Last updated on ClinicalTrials.gov

October 5, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites